The U.S. Food and Drug Administration has issued warning letters to 14 compounding pharmacies for selling products containing impure or substandard GLP-1 receptor agonist peptides, the agency announced this week. The enforcement action targets facilities that have been compounding versions of semaglutide and tirzepatide, medications that have surged in popularity for treating type 2 diabetes and obesity.
According to the FDA, laboratory testing revealed that products from these compounding pharmacies contained impurities, degradation products, or inconsistent peptide concentrations that could pose safety risks to patients. The warning letters cite violations of federal regulations governing the quality and safety standards required for compounded medications. Compounding pharmacies are permitted to create customized medications for individual patients, but they must still meet strict quality control standards.
The enforcement comes amid an unprecedented demand for GLP-1 medications, driven by their effectiveness for weight loss and the well-publicized shortages of FDA-approved brand-name products like Ozempic, Wegovy, and Mounjaro. These shortages have created opportunities for compounding pharmacies to fill the gap, but regulatory officials have expressed growing concern about the quality and safety of compounded versions entering the market.
The FDA emphasized that unlike FDA-approved medications, which undergo rigorous testing for safety, efficacy, and quality, compounded drugs are not FDA-approved and may not meet the same standards. Peptides are particularly challenging to compound properly, as they are complex biological molecules that can degrade easily or contain impurities if not manufactured under appropriate conditions.
Patients currently using compounded GLP-1 medications from any of the 14 pharmacies named in the warning letters should consult with their healthcare providers about their treatment options. The FDA has not issued a recall but is requiring the pharmacies to address the violations or face potential additional enforcement actions, including product seizure or injunctions against continuing operations.
